Federal Register / Vol. 72, No. 59 / Wednesday, March 28, 2007 / Notices 14593 

from this avian AAV are likely to find 

novel applications for gene therapy in 

humans. Furthermore because of their 

species of origin, this vector would also 

be useful in the engineering of avian 

cells. 

Inventors: Ioannis Bossis and John A. 

Chiorini (NIDCR). 

Publication: I Bossis, JA Chiorini. 

Cloning of an avian adeno-associated 

virus (AAAV) and generation of 

recombinant AAAV particles. J Virol. 

2003 Jun;77(12):6799–6810. 

Patent Status: U.S. Patent Application 

No. 10/557,662 filed 21 Dec 2006 (HHS 

Reference No. E–105–2003/0–US–03). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Jesse S. Kindra, 

J.D.; 301/435–5559; 

kindraj@mail.nih.gov 

Collaborative Research Opportunity: 

The National Institute of Dental and 

Craniofacial Research, Laboratory of Dr. 

John Chiorini, is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize gene therapy methods 

using AAV vectors. Please contact David 

W. Bradley, PhD at 

bradleyda@nidcr.nih.gov for more 

information. 

Serotonin-Deficient Knock-Out Mouse 

Description of Technology: Serotonin 

is an important modulator of many 

developmental, behavioral, and 

physiological processes, and it has been 

implicated in depression, anxiety, 

schizophrenia, obsessive compulsive 

disorders, and substance abuse. 

Serotonin’s pharmacology is extremely 

complex and it is mediated by seven of 

serotonin receptor subtypes and it is 

present in several tissues. Although it 

has been a subject of a number of 

studies, its role has been difficult to 

ascertain. To investigate the role of 

serotonin in these disorders, the murine 

gene was disrupted by homologous 

recombination. Results indicate that 

serotonin binding sites were absent in 

different brain regions (brain stem, 

frontal cortex, hippocampus, and 

striatum), and its concentrations were 

reduced by 60–80%. These mice 

represent a powerful tool for the 

investigation of behavioral and 

neuropsychiatric disorders, and 

development of drug treatments for 

these disorders. 

Applications: A model to study 

serotonin’s role in behavioral and 

neuropsychiatric disorders. 

Market: 

1. Serotonin inhibitors are most 

widely used treatment in 

neuropsychological disorders. Examples 

include Zoloft, Paxil, and Prozac. 

2. Depression effects approximately 

18.8 million U.S. citizens and over 121 

million people worldwide. 

3. Antidepressant market was worth 

$16.2 billion in 2005, and it has annual 

growth of 2% year on year. 

4. Anxiety disorders affect 40 million 

(18.1%) of the adult U.S. population. 

5. Global anxiety disorder market was 

$4.5 billion in 2006. 

Inventors: Dennis L. Murphy (NIMH) 

et al. 

Publications: 

1. RF Ren-Patterson, LW Cochran, A 

Holmes, S Sherrill, SJ Huang, T Tolliver, 

K-P Lesch. Loss of brain-derived 

neurotrophic factor gene allele 

exacerbates brain monoamine 

deficiencies and increases stress 

abnormalities of serotonin transporter 

knockout mice. J Neurosci Res. 2005 

Mar 15:79(6):756–771. 

2. DL Murphy, A Lerner, G Rudnick, 

K-P Lesch. Serotonin transporter: gene, 

genetic disorders, and 

pharmacogenetics. Mol Interv. 2004 

April:4(2):109–123. 

3. RF Ren-Patterson, D-K Kim, X 

Zheng, S Sherrill, S-J Huang, T Tolliver, 

DL Murphy. Serotonergic-like 

progenitor cells propagated from neural 

stem cells in vitro: survival with SERT 

protein expression following 

implantation into brains of mice lacking 

SERT. FASEB J. 2005 Sep:19(11):1537–

1539. 

4. Q Li, A Holmes, L Ma, LD Van de 

Kar, F Garcia, DL Murphy. Medical 

hypothalamic 5-hydroxytryptamine 

(5HT)1A receptors regulate 

neuroendocrine responses to stress and 

exploratory locomotor activity 

application of recombinant adenovirus 

containing 5-HT1A sequences. J 

Neurosci. 2004 Dec 1:24(48):10868–

10877. 

5. F Kilic, DL Murphy, G Rudnick. A 

human serotonin transporter mutation 

causes constitutive activation of 

transport activity. Mol Pharmacol. 2003 

Aug:64(2):440–446. 

6. DL Murphy, GR Uhl, A Holmes, R 

Ren-Patterson, FS Hall, I Sora, S DeteraWadleigh, K-P Lesch. Experimental gene 

interaction studies with SERT mutant 

mice as models for human polygenic 

and epistatic traits and disorders. Genes 

Brain Behav. 2003 Dec:2(6):350–364. 

7. N Ozaki, D Goldman, WH Kaye, K 

Plotnicov, BD Greenberg, J Lappalainen, 

G Rudnick, DL Murphy. Serotonin 

transporter missense mutation 

associated with a complex 

neuropsychiatric phenotype. Mol 

Psychiatry. 2003 Nov:8(11):933–936. 

Patent Status: HHS Reference No. 

B–019–1999/0—Research Tool. 

Licensing Status: This technology is 

available as a research tool under a 

Biological Materials License. 

Licensing Contact: Jennifer Wong; 

301/435–4633; wongje@mail.nih.gov. 

Dated: March 15, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–5675 Filed 3–27–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Microdialysis Probe for Accessing 

Tissue in-vivo 

Description of Technology: Available 

for licensing and commercial 

development is a microdialysis probe. 

This device permits in-vivo 

measurement of bioavailable substances 

(e.g., cytokines, growth factors, 

neuropeptides, inflammatory mediators, 

etc.) at picogram levels of concentration 

directly from soft tissue and organ 

systems. The probe may also serve as an 

in-situ drug delivery vehicle of micro 

doses of medication to specific 

anatomical sites by slow diffusion. It 

also permits measurement of efficacy of 

drug delivery, whether given orally, 

systemically or topically, at the local 


sroberts on PROD1PC70 with NOTICES
14594 Federal Register / Vol. 72, No. 59 / Wednesday, March 28, 2007 / Notices 

tissue level. It can be utilized in a 

variety of patient populations and 

conditions. For example, the probe can 

be used to monitor the local 

biochemical milieu in soft tissue and 

organ systems to provide insights into 

the pathophysiology of musculoskeletal, 

neuromuscular, rheumatic, 

gastrointestinal, renal, cardiovascular 

and endocrinologic diseases, cancers, 

dermatological conditions, and pediatric 

disorders, especially in premature 

newborns. 

The probe is made from a small-bore 

(32 gauge) needle, whose probe surface 

has been fashioned to permit near 

trauma-less entry, containing both a 

fluid delivery and recovery tube within 

the bore. A molecular exchange 

membrane is positioned about 200 

microns from the tip. Fluid flows across 

the membrane removing diffused 

molecules to a collection device. The 

rounded tip of the needle is designed to 

cause minimal tissue damage while 

allowing investigations to be performed 

on local tissue fluids. Additionally, this 

device allows simultaneous delivery of 

small concentrations of drug. In 

summary, this unique apparatus 

provides a minimally invasive means 

for sampling biological fluids in any 

human or animal organ or tissue and for 

in-situ drug-delivery, in continuous or 

incremental dosing, of extremely small 

doses. 

Applications: Measurement of 

bioavailable substances in organs and 

soft tissues; Localized drug delivery 

vehicle; Measurement of tissue drug 

levels. 

Market: Drug discovery; Tissue/fluid 

sampling; Pain management. 

Inventors: Jay Shah (NIHCC), Terence 

Martyn Phillips (ORS), Jerome V. Danoff 

(NIHCC), Lynn Gerber (NIHCC). 

Publication: JP Shah, TM Phillips, JV 

Danoff, LH Gerber. An in vivo 

microanalytical technique for measuring 

the local biochemical milieu of human 

skeletal muscle. J Appl Physiol. 2005 

Nov; 99(5):1977–1984. Epub 2005 Jul 

21. 

Patent Status: U.S. Provisional 

Application No. 60/795,176 filed 27 Apr 

2006 (HHS Reference No. E–024–2006/ 

0–US–01). 

Licensing Contact: Michael A. 

Shmilovich, Esq.; 301/435–5019; 

shmilovm@mail.nih.gov. 

Fluorescent Intracellular Calcium 

Indicators 

Description of Technology: Calcium is 

a key element in the regulation of many 

cellular processes, including muscle 

contraction, hormone excretion from 

gland cells, neurotransmitter release 

from nerve synapses, and the regulation 

of cellular metabolism. Elevated 

calcium levels are found in a number of 

diseases. 

The present invention relates to 

chromophoric or fluorescent dye 

calcium indicators that are superior for 

measurement of high concentrations of 

calcium ions due to their high 

dissociation constants. As a result of the 

high calcium ion dissociation constants, 

the perturbation resulting from 

introducing the indicator into the cell is 

greatly reduced. These calcium ion 

indicators can be measured by various 

techniques including 19F NMR 

spectroscopy, flow cytometry, and 

quantitative fluorescence techniques, 

and are useful for measuring calcium 

levels within the cytosol or within 

cellular organelles. 

Application: Research tool for 

quantifying intracellular calcium 

concentrations. 

Inventors: Robert E. London, Louis A. 

Levy, and Elizabeth Murphy (NIEHS). 

Patent Status: U.S. Patent Application 

No. 08/175,590 filed 30 Dec 1993, 

which issued as U.S. Patent No. 

5,516,911 on 14 May 1996 (HHS 

Reference No. E–015–1993/0–US–01). 

Licensing Status: Available for 

nonexclusive licensing. 

Licensing Contact: Tara Kirby, PhD; 

301/435–4426; tarak@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIEHS Laboratory of Structural 

Biology is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize this technology. Please 

contact Dr. Robert London at 919/541–

4879 or london@niehs.nih.gov for more 

information. 

Dated: March 19, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–5676 Filed 3–27–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center on Minority Health and 

Health Disparities; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center on 

Minority Health and Health Disparities 

Special Emphasis Panel, LRP for Health 

Disparities and Clinical Research-Panel B. 

Date: April 29, 2007. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6707 

Democracy Blvd./Suite 800, Bethesda, MD 

20892, (Virtual Meeting). 

Contact Person: Lorrita Watson, PhD, 

National Center on Minority Health, and 

Health Disparities, National Institutes of 

Health, 6707 Democracy Blvd., Suite 800, 

Bethesda, MD 20892–5465, (301) 402–1366, 

watsonl@ncmhd.nih.gov. 

Name of Committee: National Center on 

Minority Health and Health Disparities 

Special Emphasis Panel, NCMHD Conference 

Grant Application (R13) Review. 

Date: May 1, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892, (Virtual 

Meeting). 

Contact Person: Robert Nettey, MD, 

Scientific Review Administrator, National 

Institute on Minority Health, and Health 

Disparities, 6707 Democracy Blvd., Suite 800, 

Bethesda, MD 20892, 301–496–3996. 

Dated: March 21, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–1516 Filed 3–27–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute, Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 


sroberts on PROD1PC70 with NOTICES